Clinical Research Directory

Inclusion Criteria: * Age\>18 years * Histologic diagnosis of early-stage BC (stage I, II, III operated; luminal, HER2+, triple-negative tumors) or OC (high-grade epithelial any stage and histotype); presence of germline variant of BRCA1 or BRCA2, class 4 or 5 * Patients carrying germline variant of BRCA1 or BRCA2, class 4 or 5, in the absence of BC and/or OC, who have not undergone prophylactic mastectomy and/or bilateral ovariectomy surgery. * Patients with malignancy must have undergone surgery and be currently disease-free or in complete or partial remission in the case of OC. * Adjuvant/neoadjuvant systemic therapy as well as maintenance therapy (PARP-inhibitors for example) is permitted. * Signature of informed consent. * ECOG: 0.1. * Compliance with questionnaire completion Exclusion Criteria: * Prophylactic breast or ovarian surgery * Germinal variant of BRCA1 or BRCA2, class 1,2, 3.